183 related articles for article (PubMed ID: 31335591)
1. Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.
Archampong T; Ojewale O; Bears K; Chen Y; Lartey M; Sagoe KW; Obo-Akwa A; Gong Y; Langaee T; Kwara A
J Acquir Immune Defic Syndr; 2019 Dec; 82(4):421-425. PubMed ID: 31335591
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
[TBL] [Abstract][Full Text] [Related]
5. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.
Gu L; Han Y; Li Y; Zhu T; Song X; Huang Y; Yang F; Guan S; Xie J; Gohda J; Hosoya N; Kawana-Tachikawa A; Liu W; Gao GF; Iwamoto A; Li T; Ishida T
PLoS One; 2015; 10(8):e0134539. PubMed ID: 26288093
[TBL] [Abstract][Full Text] [Related]
6. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression.
Lartey M; Ganu VJ; Tachi K; Yang H; Anderson PL; Langaee T; Ojewale O; Boamah I; Obo-Akwa A; Antwi K; Bushman LR; Ellison L; Kwara A
AIDS; 2024 Mar; 38(3):351-362. PubMed ID: 37861682
[TBL] [Abstract][Full Text] [Related]
7. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
8. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
[TBL] [Abstract][Full Text] [Related]
9. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Archampong TN; Boyce CL; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Blackard JT; Kwara A
Antivir Ther; 2017; 22(1):13-20. PubMed ID: 27167598
[TBL] [Abstract][Full Text] [Related]
10. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
[TBL] [Abstract][Full Text] [Related]
11. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.
Wandeler G; Mauron E; Atkinson A; Dufour JF; Kraus D; Reiss P; Peters L; Dabis F; Fehr J; Bernasconi E; van der Valk M; Smit C; Gjærde LK; Rockstroh J; Neau D; Bonnet F; Rauch A;
J Hepatol; 2019 Aug; 71(2):274-280. PubMed ID: 30965070
[TBL] [Abstract][Full Text] [Related]
12. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
Lukhwareni A; Gededzha MP; Amponsah-Dacosta E; Blackard JT; Burnett RJ; Selabe SG; Kyaw T; Mphahlele MJ
Viruses; 2020 Jun; 12(6):. PubMed ID: 32545313
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
Hafkin JS; Osborn MK; Localio AR; Amorosa VK; Kostman JR; Stern JJ; De La Torre P; Mounzer K; Frank I; Gross R; Chang KM; Lo Re V
J Viral Hepat; 2014 Apr; 21(4):288-96. PubMed ID: 24597697
[TBL] [Abstract][Full Text] [Related]
14. Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.
Aurpibul L; Lumbiganon P; Hansudewechakul R; Kanjanavanit S; Bunupuradah T; Kosalaraksa P; Taeprasert P; Puthanakit T
Pediatr Infect Dis J; 2017 Apr; 36(4):401-404. PubMed ID: 28005687
[TBL] [Abstract][Full Text] [Related]
15. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
Boyd A; Bottero J; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Serfaty L; Lacombe K
J Int AIDS Soc; 2017 Feb; 20(1):21426. PubMed ID: 28362068
[TBL] [Abstract][Full Text] [Related]
16. High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Jia HH; Li KW; Chen QY; Wang XY; Harrison TJ; Liang SJ; Yang QL; Wang C; Hu LP; Ren CC; Fang ZL
Intervirology; 2018; 61(3):123-132. PubMed ID: 30368502
[TBL] [Abstract][Full Text] [Related]
17. A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
Likanonsakul S; Suntisuklappon B; Nitiyanontakij R; Prasithsirikul W; Nakayama EE; Shioda T; Sangsajja C
PLoS One; 2016; 11(1):e0147724. PubMed ID: 26807589
[TBL] [Abstract][Full Text] [Related]
18. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
Price H; Dunn D; Pillay D; Bani-Sadr F; de Vries-Sluijs T; Jain MK; Kuzushita N; Mauss S; Núñez M; Nüesch R; Peters M; Reiberger T; Stephan C; Tan L; Gilson R
PLoS One; 2013; 8(7):e68152. PubMed ID: 23874527
[TBL] [Abstract][Full Text] [Related]
19. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Huang YS; Sun HY; Chang SY; Chuang YC; Cheng A; Huang SH; Huang YC; Chen GJ; Lin KY; Su YC; Liu WC; Hung CC
Hepatol Int; 2019 Jul; 13(4):431-439. PubMed ID: 31177505
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy.
Weissmann L; Picone CM; Gouvêa MSG; Ferreira PRA; Viana MSVB; Pinho JRR; Cassenote AJF; Segurado AC
Braz J Infect Dis; 2019; 23(6):441-450. PubMed ID: 31715124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
